{
    "id": 1752,
    "fullName": "FGFR3 R248C",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "FGFR3 R248C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). R248C confers a gain of function to the Fgfr3 protein as demonstrated by constitutive ligand-independent cell proliferation (PMID: 19381019) and increased activation of the Mapk signaling pathway (PMID: 24626198).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 12442,
                    "pubMedId": 24626198,
                    "title": "Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24626198"
                },
                {
                    "id": 742,
                    "pubMedId": 19381019,
                    "title": "Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19381019"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2261,
        "geneSymbol": "FGFR3",
        "terms": [
            "FGFR3",
            "ACH",
            "CD333",
            "CEK2",
            "HSFGFR3EX",
            "JTK4"
        ]
    },
    "variant": "R248C",
    "createDate": "09/17/2014",
    "updateDate": "10/04/2018",
    "referenceTranscriptCoordinates": {
        "id": 117056,
        "transcript": "NM_000142",
        "gDna": "chr4:g.1801837C>T",
        "cDna": "c.742C>T",
        "protein": "p.R248C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13133,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Votrient (pazopanib) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 1737,
                "profileName": "FGFR3 R248C"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17668,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 R248C is included in the companion diagnostic (PMID: 31340094; NCT02365597).",
            "molecularProfile": {
                "id": 1737,
                "profileName": "FGFR3 R248C"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4006,
                "name": "bladder urothelial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15450,
                    "pubMedId": null,
                    "title": "Balversa (erdafitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018"
                },
                {
                    "id": 15824,
                    "pubMedId": 31340094,
                    "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31340094"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1030,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R3Mab inhibited ligand-independent proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019).",
            "molecularProfile": {
                "id": 1737,
                "profileName": "FGFR3 R248C"
            },
            "therapy": {
                "id": 1465,
                "therapyName": "R3Mab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 742,
                    "pubMedId": 19381019,
                    "title": "Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19381019"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13126,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGJ398 inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 1737,
                "profileName": "FGFR3 R248C"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13129,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dovitinib (TKI258) inhibited growth of transformed cells expressing FGFR3 R248C in culture (PMID: 23786770).",
            "molecularProfile": {
                "id": 1737,
                "profileName": "FGFR3 R248C"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2132,
                    "pubMedId": 23786770,
                    "title": "Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23786770"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17152,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (BCL2001) that supported FDA approval, Balversa (erdafitinib) treatment resulted in an objective response rate of 40% (40/99, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations and FGFR3 R248C is included in the companion diagnostic (PMID: 31340094; NCT02365597).",
            "molecularProfile": {
                "id": 1737,
                "profileName": "FGFR3 R248C"
            },
            "therapy": {
                "id": 1028,
                "therapyName": "Erdafitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2671,
                "name": "transitional cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15450,
                    "pubMedId": null,
                    "title": "Balversa (erdafitinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212018"
                },
                {
                    "id": 15824,
                    "pubMedId": 31340094,
                    "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31340094"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1737,
            "profileName": "FGFR3 R248C",
            "profileTreatmentApproaches": [
                {
                    "id": 7526,
                    "name": "FGFR3 Inhibitor",
                    "profileName": "FGFR3 R248C"
                },
                {
                    "id": 7527,
                    "name": "FGFR Inhibitor (Pan)",
                    "profileName": "FGFR3 R248C"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 117056,
            "transcript": "NM_000142",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117047,
            "transcript": "XM_006713868",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117048,
            "transcript": "XM_006713869",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117055,
            "transcript": "NM_001163213",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117053,
            "transcript": "XM_006713872",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117054,
            "transcript": "XM_006713873",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117049,
            "transcript": "XM_006713870",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117051,
            "transcript": "XM_011513420",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117052,
            "transcript": "XM_011513422",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117050,
            "transcript": "XM_006713871",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 117057,
            "transcript": "NM_022965",
            "gDna": "chr4:g.1801837C>T",
            "cDna": "c.742C>T",
            "protein": "p.R248C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}